Key Event34th AGM approved FY2026 audited financials and reappointed directors.
Key EventAll five AGM resolutions passed with requisite majority
Krebs Biochemicals & Industries Ltd (KREBSBIO)
·Next Day Close·+1.55%·₹57
Key EventTrading window closes before Q2 results announcement
ImpactShareholders must avoid trading during the restricted period to comply with insider regulations.Sign up to read impact
Krebs Biochemicals & Industries Ltd (KREBSBIO)
·Next Day Close·-1.88%·₹54.95
Key Event34th AGM scheduled for 29 September 2026 via video conferencing with e-voting facility
ImpactShareholders must vote remotely on key resolutions including related party transactions and director reappointments, with voting rights tied to shareholding as of 23 September 2026.Sign up to read impact
Krebs Biochemicals & Industries Ltd (KREBSBIO)
·Next Day Close·-1.88%·₹54.95
Key EventApproval sought for related party transactions with Ipca Laboratories up to ₹120 Cr annually and ratification of cost auditor remuneration.
ImpactThe company remains loss-making but is focusing on operational revival and strategic partnerships to stabilize financial position and future profitability.Sign up to read impact
Krebs Biochemicals and Industries Limited (KREBSBIO)
·Next Day Close·+7.03%·₹57.25
Key EventBoard approved unaudited Q1 FY26 results and auditor review
ImpactShareholders now have official Q1 results to assess near-term performance.Sign up to read impact
Krebs Biochemicals and Industries Limited (KREBSBIO)
·Next Day Close·+0.3%·₹59.41
Krebs Biochemicals & Industries Limited received SEBI-mandated certificates from its share transfer agent KFIN Technologies for the quarter ended June 30, 2026, confirming compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The filing includes certificates from NSDL and CDSL validating dematerialization/rematerialization details for all listed exchanges.
Sign up to read summaryKrebs Biochemicals and Industries Limited (KREBSBIO)
·Next Day Close·-6.61%·₹61.5
Krebs Biochemicals announced a scheme of amalgamation with Ipca Laboratories effective April 1, 2026, where the company will merge into Ipca without cash consideration, issuing 7 fully paid shares of Re. 1 each for every 200 shares held in Krebs. The merger aims to secure API supply, reduce administrative burdens, and leverage Ipca's scale, though Krebs reported only Rs. 26 crores in standalone income for FY2026.
Sign up to read summaryKrebs Biochemicals and Industries Limited (KREBSBIO)
·Next Day Close·-6.61%·₹61.5
Krebs Biochemicals announced board approval of its amalgamation with Ipca Laboratories under Sections 230-232 of the Companies Act, subject to regulatory approvals, with an effective date of April 1, 2026. The merger will consolidate operations, secure critical API supply chains, and eliminate administrative redundancies, while Krebs will issue shares to Ipca shareholders without cash consideration.
Sign up to read summaryKrebs Biochemicals and Industries Limited (KREBSBIO)
·Next Day Close·+2.78%·₹65.85
Krebs Biochemicals & Industries Limited announced that its trading window will close on June 30, 2026, ahead of the unaudited Q1 2026 financial results, affecting insiders and connected persons.
Sign up to read summary